Pierre Clément

Pierre Clément

Auto-generated profile, based on publicly available information

Pierre Clément

Pelvipharm Laboratories, Orsay, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2013 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
CCClément Chéhensse
Clément Chéhensse
SBStéphane Bahrami
Stéphane Bahrami
PDPierre Denys
Pierre Denys
PCPierre Clément
Pierre Clément
JBJacques Bernabé
Jacques Bernabé
FGFrançois Giuliano
François Giuliano
After spinal cord injury (SCI), most men cannot ejaculate without medical assistance. A major advance in the knowledge of the spinal control of ejaculation has been achieved with the discovery of a spinal generator of ejaculation (SGE) in the rat. The aim of this report was to review studies about ejaculation after SCI in order to revisit the spinal control of ejaculation and especially to assess the existence of an SGE in man. Studies were identified from Embase, PubMed, EBSCOhost and Cochrane Library. Studies were eligible when they specify the occurrence of antegrade ejaculation as a function of the neurological characterization of SCI. Studies were excluded when ejaculation was elicited by rectal electrical stimulation or when ejaculation could not be discriminated from climax. Meta-analyses were performed to assess the reference ejaculation rates for each procedure used to elicit ejaculation, i.e. masturbation or coïtus, penile vibratory stimulation (PVS) or acetylcholine esterase (AchE) inhibitors prior to masturbation. Subgroup analyses were performed according to the procedure used to elicit ejaculation on (i) the completeness of the SCI and (ii) the upper and lower limits of the SCI. To assess the existence of an SGE, the effect of concurrent lesions of different spinal segments was assessed by means of a stratified bivariate analysis. From 523 studies, 45 were selected (n = 3851). Ejaculation occurred in response to masturbation or coïtus, PVS or AchE inhibitors followed by masturbation in, respectively, 11.8% (n = 1161), 47.4% (n = 597) and 54.7% (n = 309) of patients with complete SCI and in, respectively, 33.2% (n = 343), 52.8% (n = 305) and 78.1% (n = 32) of patients with incomplete SCI. Ejaculation, in the case of complete lesion of the sympathetic centres (T12 to L2), of the parasympathetic and somatic centres (S2–S4) or of all spinal ejaculation centres (T12 to S5) occurred in response to PVS in none of the patients (respectively, n = 5, n = 4 and n = 21) and in response to AchE inhibitors followed by masturbation in 4.9% (n = 61), 30.8% (n = 26) and 0% (n = 16) of the patients, respectively. Ejaculation in response to PVS or AchE inhibitors prior to masturbation was rhythmic forceful in 97.9% (n = 48) of the patients with complete lesion strictly above Onuf's nucleus (segments S2–S4). Complete lesion of the S2–S4 segments precluded the occurrence of rhythmic forceful ejaculation (n = 5). Controlling for the number of the injured segments between T12 and L2, the ejaculation rate sharply decreased when the lesion extended to the L3 segment and below. The results reinforce the crucial roles of the spinal sympathetic and parasympathetic centres for emission and the somatic centre for expulsion. The spinal segments between L2 and S2 is more than a pathway to connect the ejaculation centres and likely harbours an SGE in man located in the L3, L4 and L5 segments.

1 July 2012 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
FGFrançois Giuliano
François Giuliano
PCPierre Clèment
Pierre Clèment
Significant intra- and interindividual variability has been observed in response to use of pharmacological agents in treatment of HIV infection. Treatment of HIV infection is limited by high rates of adverse drug reactions and development of resistance in a significant proportion of patients as a result of suboptimal drug concentrations. The efficacy of antiretroviral therapy is challenged by the emergence of resistant HIV-1 mutants with reduced susceptibility to antiretroviral drugs. Moreover, pharmacotherapy of patients infected with HIV is challenging because a great number of comorbidities increase polypharmacy and the risk for drug-drug interactions. Drug-metabolizing enzymes and drug transporters regulate drug access to the systemic circulation, target cells, and sanctuary sites. These factors, which determine drug exposure, along with the emergence of mutations conferring resistance to HIV medications, could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. In this review, the major factors affecting the disposition of antiretroviral drugs, including key drug-metabolizing enzymes and membrane drug transporters, are outlined. Genetic polymorphisms affecting the activity and/or the expression of cytochromes P450 or UGT isozymes and membrane drug transport proteins are highlighted and include such examples as the association of neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine, and hyperbilirubinemia with indinavir and atazanavir. Mechanisms of drug resistance conferred by specific viral mutations are also reviewed, with particular attention to replicative viral fitness and transmitted HIV drug resistance with the objectives of providing a better understanding of mechanisms involved in HIV drug resistance and helping health care providers to better manage interpatient variability in drug efficacy and toxicity.

27 March 2013 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
PCPierre Clément
Pierre Clément
JBJacques Bernabé
Jacques Bernabé
SCSandrine Compagnie
Sandrine Compagnie
LALaurent Alexandre
Laurent Alexandre
SMStewart McCallum
Stewart McCallum
FGFrançois Giuliano
François Giuliano
Background and Purpose: Oxytocin (OT) plays a major role in the control of male sexual responses. Notably, blockade of OT receptors has been reported to inhibit ejaculation in animals. The study aimed to investigate the action of a highly selective, non‐peptide OT antagonist GSK557296 in a model of pharmacologically induced ejaculation in anaesthetized rats. The site of action was assessed by investigating different delivery routes for this compound.Experimental Approach: Urethane‐anaesthetized Wistar rats were implanted with a cerebral ventricle cannula for i.c.v. injections or with a subdural catheter for intrathecal (i.t.) GSK557296 injections. Occurrence of ejaculation was assessed following i.v. 7‐hydroxy‐2‐(di‐N‐propylamino)tetralin (7‐OH ‐DPAT), a dopamine D3 receptor agonist. In addition, seminal vesicle pressures (SVP) and bulbospongiosus muscle (BS) EMG were recorded as physiological markers of emission and expulsion phases of ejaculation respectively.Key Results: Highest i.v. GSK557296 dose reduced occurrence of ejaculation and increases in SVP but had no effect on BS‐EMG. I.c.v. GSK557296 dose dependently inhibited ejaculation, increases in SVP and BS contractions. At spinal thoracic level, GSK557296 dose dependently inhibited ejaculation and increases in SVP but BS‐EMG was impaired only with the highest dose. When delivered at lumbar level, GSK557296 dose dependently inhibited ejaculation, increases in SVP and BS contractions.Conclusions and Implications: In the 7‐OH ‐DPAT‐induced ejaculation model, GSK557296 acts peripherally and centrally to inhibit ejaculation with different modalities. Blockade of brain OT receptors seems to be the most effective mechanism of action. Targeting central OT receptors with highly selective antagonist seems a promising approach for the treatment of premature ejaculation.

1 April 2009 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
PCPierre Clément
Pierre Clément
CPChiara Pozzato
Chiara Pozzato
CHChristian Heidbreder
Christian Heidbreder
LALaurent Alexandre
Laurent Alexandre
FGFrancois Giuliano
Francois Giuliano
SMSergio Melotto
Sergio Melotto

1 October 2012 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
PCPierre Clément
Pierre Clément
MLMiguel Laurin
Miguel Laurin
SCSandrine Compagnie
Sandrine Compagnie
PFPatricia Facchinetti
Patricia Facchinetti
JBJacques Bernabé
Jacques Bernabé
FGFrançois Giuliano
François Giuliano

1 August 2009 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
ABAren J. Borgdorff
Aren J. Borgdorff
ARAnne-Sophie Rössler
Anne-Sophie Rössler
PCPierre Clément
Pierre Clément
JBJacques Bernabé
Jacques Bernabé
LALaurent Alexandre
Laurent Alexandre
FGFrançois Giuliano
François Giuliano